HAZEN; Meredith
Patent Applications and Registrations
Patent applications and USPTO patent grants for HAZEN; Meredith.The latest application filed is for "anti-tigit antibodies and methods of use".
- HAZEN; Meredith - Belmont CA
- Hazen; Meredith - South San Francisco CA
- Hazen; Meredith - San Mateo CA
| Patent | Date |
|---|---|
| Anti-tigit Antibodies And Methods Of Use App 20220064286 - GROGAN; Jane L. ; et al. | 2022-03-03 |
| Method of treating asthma using an IL-13 antibody Grant 11,226,341 - Arron , et al. January 18, 2 | 2022-01-18 |
| Anti-tigit Antibodies And Methods Of Use App 20210253693 - GROGAN; Jane L. ; et al. | 2021-08-19 |
| Anti-tigit Antibodies And Methods Of Use App 20210032328 - GROGAN; Jane L. ; et al. | 2021-02-04 |
| Anti-interleukin-33 Antibodies And Uses Thereof App 20210002361 - HASS; Philip E. ; et al. | 2021-01-07 |
| Anti-interleukin-33 antibodies and uses thereof Grant 10,723,795 - Hass , et al. | 2020-07-28 |
| Anti-tigit Antibodies And Methods Of Use App 20190119376 - GROGAN; Jane L. ; et al. | 2019-04-25 |
| Diagnosis And Treatments Relating To Th2 Inhibition App 20190120854 - Arron; Joseph R. ; et al. | 2019-04-25 |
| Anti-interleukin-33 Antibodies And Uses Thereof App 20190092852 - HASS; Philip E. ; et al. | 2019-03-28 |
| Anti-interleukin-33 antibodies and uses thereof Grant 10,093,730 - Hass , et al. October 9, 2 | 2018-10-09 |
| Anti-TIGIT antibodies and methods of use Grant 10,047,158 - Grogan , et al. August 14, 2 | 2018-08-14 |
| Anti-tigit Antibodies And Methods Of Use App 20180186875 - GROGAN; Jane L. ; et al. | 2018-07-05 |
| Method of reducing blood glucose by administering RON agonists Grant 10,005,848 - Egen , et al. June 26, 2 | 2018-06-26 |
| Diagnosis and treatments relating to TH2 inhibition Grant 9,995,755 - Arron , et al. June 12, 2 | 2018-06-12 |
| Diagnosis and treatments relating to TH2 inhibition Grant 9,684,000 - Arron , et al. June 20, 2 | 2017-06-20 |
| Anti-tigit Antibodies And Methods Of Use App 20170088613 - GROGAN; Jane L. ; et al. | 2017-03-30 |
| Compositions and methods for the diagnosis and treatment of tumor Grant 9,580,514 - Bhakta , et al. February 28, 2 | 2017-02-28 |
| Anti-interleukin-33 Antibodies And Uses Thereof App 20160168242 - HASS; Philip E. ; et al. | 2016-06-16 |
| Anti-crth2 Antibodies And Methods Of Use App 20160090422 - REIF; Karin ; et al. | 2016-03-31 |
| Ron Compositions And Methods Of Use Thereof App 20160032013 - EGEN; JACKSON G. ; et al. | 2016-02-04 |
| Compositions And Methods For The Diagnosis And Treatment Of Tumor App 20150098946 - Bhakta; Sunil ; et al. | 2015-04-09 |
| Anti-crth2 Antibodies And Methods Of Use App 20140328849 - REIF; Karin ; et al. | 2014-11-06 |
| NLRR-1 antagonists and uses thereof Grant 8,691,222 - Hazen , et al. April 8, 2 | 2014-04-08 |
| Diagnosis And Treatments Relating To Th2 Inhibition App 20140044645 - Arron; Joseph R. ; et al. | 2014-02-13 |
| Diagnosis And Treatments Relating To Th2 Inhibition App 20140044702 - Arron; Joseph R. ; et al. | 2014-02-13 |
| Diagnosis And Treatments Relating To Th2 Inhibition App 20120156194 - Arron; Joseph R. ; et al. | 2012-06-21 |
| Nlrr-1 Antagonists And Uses Thereof App 20100330082 - Hazen; Meredith ; et al. | 2010-12-30 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 